2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13A.05 Prognostic Laboratory Parameters in Imfirst: Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

EP.13A.05 Prognostic Laboratory Parameters in Imfirst: Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Back to course

Pdf Summary

The exploratory analysis in the IMfirst study investigates the potential of laboratory parameters in predicting prognosis for patients with extensive-stage small cell lung cancer (ES-SCLC) treated with first-line atezolizumab and chemotherapy. The study involves 155 patients, examining factors that could predict long-term benefit (LTB), defined as survival beyond 24 months post-treatment.<br /><br />Key findings reveal that patients with LTB had significantly lower baseline levels of leukocytes, neutrophils, neutrophil-to-lymphocyte ratio (NLR), platelet-albumin-bilirubin (PALBI) score, alkaline phosphatase (ALP), aspartate aminotransferase (AST), calcium, and lactate dehydrogenase (LDH) compared to those without LTB. Notably, LTB patients showed higher chloride levels. These parameters were significantly associated with overall survival (OS) and progression-free survival (PFS) in the univariate analyses.<br /><br />In multivariate analyses, ALP, phosphate, and bilirubin appeared as independent risk factors for OS, while phosphate alone was an independent risk factor for PFS. Furthermore, during treatment, reductions in leukocyte, neutrophil counts, and PALBI scores were observed during induction therapy. Conversely, ALP and AST levels remained stable throughout treatment, while LDH levels initially decreased then stabilized.<br /><br />The study suggests these laboratory parameters could have prognostic value, potentially aiding in the risk assessment for ES-SCLC patients undergoing chemo-immunotherapy. Still, it emphasizes the need for further prospective studies to validate these findings. Such parameters could be instrumental in tailoring individual patient treatment plans and improving clinical outcomes.<br /><br />The study presented its findings at the 2024 World Conference on Lung Cancer. The research underscores the complexity of SCLC prognosis and seeks to enhance metastatic cancer treatments by integrating specific baseline laboratory parameters to inform clinical strategies.

Asset Subtitle

Javier de Castro

Meta Tag

Speaker Javier de Castro

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

extensive-stage small cell lung cancer

ES-SCLC

atezolizumab

chemotherapy

long-term benefit

laboratory parameters

overall survival

progression-free survival

prognostic value

World Conference on Lung Cancer